Rationale for a single-pill combination of perindopril arginine and amlodipine besylate

Journal of the American Society of Hypertension

Volumn 9, Issue 4, 2015, Pages 257-265

  Elliott, William J ^a  

^a Pacific Northwest University of Health Sciences   (United States)

Author keywords

Cardiovascular events; fixedeffects; heart failure; network and Bayesian metaanalyses; randomeffects

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS PERINDOPRIL; ATENOLOL; CANDESARTAN; CHLORTALIDONE; FOSINOPRIL; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LISINOPRIL; METOPROLOL; RAMIPRIL; VALSARTAN; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; PERINDOPRIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DRUG COMBINATION;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; PERINDOPRIL;

EID: 84928416355     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2014.12.012     Document Type: Article

References (50)

1. P.A. James, S. Oparil, B.L. Carter, W.C. Cushman, C. Dennison-Himmelfarb, and J. Handler 2014 Evidence-based guidelines for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
2. M.A. Weber, E.L. Schiffrin, W.B. White, S. Mann, L.H. Lindholm, and J.G. Kenerson Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension J Clin Hypertens (Greenwich) 16 2014 14 26
3. G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, and M. Böhm 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the management of arterial hypertension J Hypertens 31 2013 1925 1938
4. World Health Organization A global brief on hypertension: Silent killer, global public health crisis 2013 Switzerland Geneva 40 Available at http://www.apps.who.int/iris/bitstream/10665/79059/1/WHO-DCO-WHD-2013.2-eng.pdf Accessed October 20, 2013
5. Centers for Disease Control and Prevention Racial/ethnic disparities in the awareness, treatment, and control of hypertension - United States, 2003-2010 MMWR Morb Mortal Wkly Rep 62 2013 351 355
6. B.M. Egan, Y. Zhao, and R.N. Axon US trends in prevalence, awareness, treatment and control of hypertension: 1998-2008 JAMA 303 2010 2043 2050
7. C.K. Chow, K.K. Teo, S. Rangarajan, S. Islam, R. Gupta, and A. Avezum Prevalence, awareness, treatment and control of hypertension in rural and urban communities in high-, middle-, and low-income countries JAMA 310 2013 959 968
8. N.R.C. Campbell, R. Brant, H. Johansen, R.L. Walker, A. Wielgosz, J. Onysko for the Canadian Hypertension Education Program Outcomes Research Task Force Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada Hypertension 53 2009 128 134
9. D.L. Hoyert, and J. Zu Deaths: Preliminary data for 2011 Natl Vital Stat Rep 61 6 2012 1 52 Available at http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61-06.pdf Accessed October 20, 2013
10. M.G. Jaffe, G.A. Lee, J.D. Young, S. Sidney, and A.S. Go Improved blood pressure control associated with a large-scale hypertension program JAMA 310 2013 699 705
11. H. Makani, S. Bangalore, J. Romero, O. Wever-Pinzon, and F.H. Messerli Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema Am J Med 124 2011 128 135
12. W.J. Elliott Reduction of amlodipine-associated edema by inhibitors of the renin-angiotensin system: meta-analyses of parallel-group randomized clinical trials [abstract] J Clin Hypertens (Greenwich) 15 Suppl. 1 2013 A22
13. T. Lumley Network meta-analysis for indirect treatment comparisons Stat Med 21 2002 2313 2324
14. D.J. Lunn, A. Thomas, N. Best, and D. Spiegelhalter WinBUGS - A Bayesian modeling framework: concepts, structure, and extensibility Stat Comp 10 2000 325 337
15. S.-Y. Lee, and X.-Y. Song Bayesian analysis of structural equation models with dichotomous variables Stat Med 22 2003 3073 3088
16. P. Tatti, M. Pahor, R.P. Byington, P. DiMauro, R. Guarisco, and G. Strollo Outcome results of the Fosinopril Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM Diabetes Care 21 1998 1779 1780
17. B. Pitt, R.P. Byington, C.D. Furberg, D.B. Hunninghake, B.G. Mancini, and M.E. Miller Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events Circulation 102 2000 1503 1510
18. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
19. S. Julius, S. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, and L. Hansson Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
20. B. Dahlöf, P.S. Sever, N.R. Poulter, H. Wedel, D.G. Beevers, and M. Caulfield Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 366 2005 895 906
21. T. Ogihara, K. Nakao, T. Fukui, K. Fukiyama, K. Ueshima, K. Oba for the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial Hypertension 51 2008 393 398
22. K. Jamerson, M.A. Weber, G.L. Bakris, B. Dahlöf, B. Pitt, V. Shi for the ACCOMPLISH Trial Investigators Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
23. H. Narumi, H. Takano, S. Shindo, M. Fujita, H. Mizuma, Y. Kuwabara for the Valsartan Amlodipine Randomized Trial Investigators Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial Hypertens Res 34 2011 62 69
24. T. Muramatsu, K. Matsushita, K. Yamashita, T. Kondo, K. Maeda, S. Shintani for the Nagoya Heart Study Investigators Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: Nagoya Heart Study Hypertension 59 2012 580 586
25. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes N Engl J Med 345 2001 851 860
26. T. Berl, L.G. Hunsicker, J.B. Lewis, M.A. Pfeffer, J.G. Porush, J.L. Rouleau Irbesartan Diabetic Nephropathy Trial Collaborative Study Group Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy Ann Intern Med 138 2003 542 549
27. L.Y. Agodoa, L. Appel, G.L. Bakris, G. Beck, J. Bourgoignie, J.P. Briggs African American Study of Kidney Disease and Hypertension (AASK) Study Group Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial JAMA 285 2001 2719 2728
28. K. Norris, J. Bourgoigne, J. Gassman, L. Hebert, J. Middleton, R.A. Phillips for the AASK Study Group Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial Am J Kidney Dis 48 2006 739 751
29. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
30. A. Patel the ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 2007 829 840
31. K.M. Fox the EUROPA Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (The EUROPA study) Lancet 362 2003 782 788
32. N.S. Beckett, R. Peters, A.E. Fletcher, J.A. Staessen, L. Liu, and D. Dumitrascu Treatment of hypertension in patients 80 years of age or older N Engl J Med 358 2008 1887 1898
33. J.J. Brugts, T. Ninomiya, E. Boersma, W.J. Remme, M. Bertrand, and R. Ferrari The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials Eur Heart J 30 2009 1385 1394
34. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients N Engl J Med 342 2000 145 153
35. E. Braunwald, M.J. Domanski, S.E. Fowler, N.L. Geller, B.J. Gersh, J. Hsia The PEACE Trial Investigators Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med 351 2004 2058 2068
36. ONTARGET Investigators Telmisartan, ramipril or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
37. B.M. Psaty, N.S. Weiss, and C.D. Furberg Recent trials in hypertension: compelling science or commercial speech? JAMA 295 2006 1704 1706
38. S. Sciarretta, F. Palano, G. Tocci, R. Baldini, and M. Volpe Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk Arch Intern Med 171 2011 384 394
39. W.J. Elliott, S. Basu, and P.M. Meyer Network meta-analysis of heart failure prevention by antihypertensive drugs [Letter] Arch Intern Med 171 2011 472 473
40. P. Meurin The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension Am J Cardiovasc Drugs 6 2006 327 334
41. M.E. Bertrand, R. Ferrari, W.J. Remme, M.L. Simoons, J.W. Deckers, K.M. Fox on behalf of the EUROPA Investigators Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post-hoc analysis of the EUROPA study Am Heart J 59 2010 795 802
42. J. Chalmers, H. Arima, M. Woodward, G. Mancia, N. Poulter, and Y. Hirakawa Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial Hypertension 63 2014 259 264
43. R. Ferrari, and E. Boersma The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review Expert Rev Cardiovasc Ther 11 2013 705 717
44. L.C. van Vark, M. Bertrand, K.M. Akkerhuis, J.J. Brugts, K. Fox, and J.J. Mourad Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients Eur Heart J 33 2012 2088 2097
45. G. Savarese, P. Costanzo, J.G.F. Cleland, E. Vassallo, D. Ruggiero, and G. Rosano A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure J Am Coll Cardiol 61 2013 131 142
46. J. Cheng, W. Zhang, X. Zhang, F. Han, X. Li, and X. He Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis JAMA Intern Med 174 2014 773 785
47. W.J. Elliott, and P.M. Meyer Incident diabetes in clinical trials of antihypertensive drugs Lancet 369 2007 201 207 errata: 1518
48. W.J. Elliott, J. Whitmore, J.D. Feldstein, and G.L. Bakris Efficacy and safety of perindopril arginine + amlodipine in hypertension J Am Soc Hypertens 9 2015 266 274
49. S. Laurent, G. Parati, I. Chazova, Y. Sirenko, A. Erglis, and A. Laucevicius Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as first-step treatment in hypertension J Hypertens 33 2015 653 662
50. G. Mancia, R. Asmar, C. Amodeo, J.J. Mourad, S. Taddei, and M.A. Gamba Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine J Hypertens 33 2015 401 411